Company attributes
Industry
B2X
0
CEO
Pitchbook URL
Number of Employees (Ranges)
1 – 100
Email Address
contact@coavetx.com
bd@coavetx.com
Full Address
29 rue du faubourg saint jacques, PARIS, FR
Founded Date
2014
Total Funding Amount (USD)
94,190,000
Latest Funding Round Date
July 21, 2021
Latest Funding Type
Patents Assigned (Count)
1
Country
Headquarters
Other attributes
Company Operating Status
Active
Latest Funding Round Amount (USD)
38,900,000
We are pushing the boundaries of gene therapy through application of our AAV-Ligand Conjugates platform (ALIGATER) that enables targeted delivery, enhanced gene transduction and tissue distribution to improve the effectiveness of advanced gene therapies for rare diseases.
Our strategy is to advance a pipeline of novel therapies targeting rare ocular and CNS diseases where targeted gene therapy has the potential to be most effective, where there is a clear unmet need and where success will provide rapid validation of our ALIGATER platform.
Timeline
No Timeline data yet.
Funding Rounds
Products
Acquisitions
SBIR/STTR Awards
Patents
Further Resources
No Further Resources data yet.
